ID   HROC69
AC   CVCL_1G06
SY   HROC69P
DR   cancercelllines; CVCL_1G06
DR   CLS; 300828
DR   Cosmic; 2795028
DR   GEO; GSM1448080
DR   Wikidata; Q54895301
RX   PubMed=25926053;
RX   PubMed=27087592;
RX   PubMed=31601052;
CC   From: Linnebacher, Michael; University of Rostock; Rostock; Germany.
CC   Population: Caucasian.
CC   HLA typing: A*26:01,33:01; B*18:01,52:01; C*12:02,12:03; DQB1*03:01,06:01; DRB1*11:04,15:02 (Direct_author_submission).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=27087592).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu7Ter (c.19G>T); ClinVar=VCV000493079; Zygosity=Unspecified (PubMed=27087592).
CC   Sequence variation: Mutation; HGNC; HGNC:6769; SMAD3; Simple; p.Ala382Val (c.1145C>T); dbSNP=rs779602560; Zygosity=Unspecified (PubMed=27087592).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=27087592).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Colon, ascending; UBERON=UBERON_0001156.
ST   Source(s): CLS=300828; PubMed=25926053; PubMed=27087592
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,12,13 (PubMed=25926053)
ST   D13S317: 12 (CLS=300828; PubMed=27087592)
ST   D16S539: 11,12 (CLS=300828; PubMed=27087592)
ST   D16S539: 12,13 (PubMed=25926053)
ST   D21S11: 29,33.2
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   TH01: 7,9.3 (CLS=300828; PubMed=25926053)
ST   TH01: 7,10 (PubMed=27087592)
ST   TPOX: 8,12
ST   vWA: 17,19 (CLS=300828; PubMed=25926053)
ST   vWA: 17,20 (PubMed=27087592)
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_YD53 ! B-LCL-HROC69
OI   CVCL_1G07 ! HROC69 T0 M2
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 10-04-25; Version: 23
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=27087592; DOI=10.1038/srep24671; PMCID=PMC4834534;
RA   Kuehn F., Mullins C.S., Krohn M., Harnack C., Ramer R., Kramer O.H.,
RA   Klar E., Huhns M., Linnebacher M.;
RT   "Establishment and characterization of HROC69 -- a Crohn s related
RT   colonic carcinoma cell line and its matched patient-derived
RT   xenograft.";
RL   Sci. Rep. 6:24671-24671(2016).
//
RX   PubMed=31601052; DOI=10.3390/cancers11101520; PMCID=PMC6826890;
RA   Mullins C.S., Micheel B., Matschos S., Leuchter M., Burtin F.,
RA   Krohn M., Huhns M., Klar E., Prall F., Linnebacher M.;
RT   "Integrated biobanking and tumor model establishment of human
RT   colorectal carcinoma provides excellent tools for preclinical
RT   research.";
RL   Cancers (Basel) 11:1520.1-1520.18(2019).
//